World Equity Group’s CorMedix CRMD Stock Holding History

World Equity Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,400	Closed	-$69.2K	–	317
2023 Q4	$69.2K	Hold	18,400	–	–	0.01%	323
2023 Q3	$68.1K	Buy	+18,400	New	+$73.2K	0.01%	328

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

World Equity Group's CRMD Position: Q1 2024 in Review

World Equity Group sold out of CorMedix (CRMD) in Q1 2024, closing a stake of 18,400 shares — an estimated $69.2K sold.

World Equity Group first reported a position in CRMD in Q3 2023 and held it in 2 quarters. The position peaked at $69.2K in Q4 2023. 91 funds tracked by Wall St. Rank hold CRMD as of Q1 2024.

World Equity Group reported no remaining CorMedix position as of Q1 2024 after selling out during the quarter.
World Equity Group sold 18,400 CorMedix shares in Q1 2024, an estimated $69.2K.
World Equity Group first reported a position in CorMedix in Q3 2023 and held it in 2 quarters.
World Equity Group's CorMedix position peaked at $69.2K in Q4 2023.
91 funds tracked by Wall St. Rank held CorMedix as of Q1 2024.

Based on World Equity Group's 13F filing for Q1 2024, filed 18 Jul 2024.